2Hajat C, Hajat S, Sharma P. Effects of poststroke pyststroke pyrexia on stroke outcome: a meta-analysis of studies on patients. Stroke, 2000, 31(2): 410-414.
3Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year: National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med, 1999, 340(23): 1781-1787.
4Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke. Neurology, 2000, 55(7): 1649-1655.
5The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines. ForCardiopulmonary Resuscitaion and Emergency Cardiovascular Care, part 7: the Era of Reperfusion: section 2: Acute Stroke. Circulation, 2000, 102(8 suppl): 204-216.
6Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke. Stroke, 2002, 33(7): 1934-1942.
7Diener HC, Ringelstein EB, von Kummer R, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial: Therapy of Patients with Acute Stroke(TOPAS) Investigators. Stroke, 2001, 32(1): 22-29.
8Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest, 2001, 119(6): 300S-320S.
9Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treament of acute ischemic stroke: the STAT Study: a randomized controlled trial: Stroke Treatment with Ancrod Trial. JAMA, 2000, 283(18): 2395-2403.
10Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke, 2000, 31(2): 347-354.
